CO

Cambridge Cognition Holdings PLCLSE Cambridge Cognition Stock Report

Last reporting period 30 Jun, 2024

Updated 05 Nov, 2024

Last price

Market cap $B

0.02

Micro

Exchange

XLON - London Stock Exchange

COG.L Stock Analysis

CO

Uncovered

Cambridge Cognition Holdings PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-2/100

Low score

Market cap $B

0.02

Dividend yield

Shares outstanding

34.734 B

Cambridge Cognition Holdings Plc is a neuroscience digital health company, which engages in the development of digital health products to better understand, detect, and treat conditions affecting brain health. The company is engaged in optimizing the assessment of cognition for better brain health with scientifically validated digital health solutions. Its neuroscience technology solutions demonstrate the value of drug treatments, detect early signs of cognitive impairment for appropriate intervention, and are a major component in the research and understanding of brain health. Its products include CANTAB Recruit, CANTAB Connect, Cognition Kit, Cognition eCOA, CANTAB Connect Research, CANTAB Mobile, CANTAB BrainHealth, CANTAB Insight and NeuroVocalix. Its CANTAB Connect offers digital cognitive assessment solutions for pharmaceutical clinical trials in therapeutic areas. Its Cognition Kit is a custom-designed digital health platform delivering wearable and smartphone applications for high-frequency data collection to demonstrate treatment efficacy and increase the understanding of a disease and a patient's response to medication.

View Section: Eyestock Rating